肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

J CIin Invest：华人科学家发现增强肿瘤免疫治疗的潜在新靶点

2018-05-24 佚名 细胞

华人科学家肿瘤免疫治疗潜在新靶点
关注

PIM激酶是一个高度保守的丝氨酸/酪氨酸激酶家族，由PIM-1，PIM-2和PIM-3三个成员组成，其中PIM-2在造血细胞中表达，通过对靶向底物进行磷酸化来影响细胞存活，增殖，转录激活和蛋白质翻译。之前一些研究表明PIM-2激酶参与多种癌细胞类型的存活和增殖，其中包括B细胞淋巴瘤，多发性骨髓瘤和前列腺癌，表明PIM-2可能是癌症治疗的一个潜在靶点。

PIM激酶是一个高度保守的丝氨酸/酪氨酸激酶家族，由PIM-1，PIM-2和PIM-3三个成员组成，其中PIM-2在造血细胞中表达，通过对靶向底物进行磷酸化来影响细胞存活，增殖，转录激活和蛋白质翻译。之前一些研究表明PIM-2激酶参与多种癌细胞类型的存活和增殖，其中包括B细胞淋巴瘤，多发性骨髓瘤和前列腺癌，表明PIM-2可能是癌症治疗的一个潜在靶点。

最近来自南卡罗来纳医科大学的华人科学家Xue-Zhong Yu等人研究了PIM激酶在骨髓移植和肿瘤免疫的T细胞应答过程中发挥的作用。他们首先发现PIM-2能够对同种异型抗原产生的T细胞应答进行负调控，而PIM-1和PIM-3发挥正向调控作用。在进行了异源基因骨髓移植之后，缺失了PIM-2的T细胞出现向Th1亚群分化，增殖和向靶器官迁移增加的情况，这导致出现更加严重的移植物抗宿主疾病，重新恢复PIM-2的表达能够显着改善因T细胞缺失PIM-2而出现的移植物抗宿主疾病。

从另一方面来说，缺失了PIM-2的小鼠也会排斥同基因肿瘤，这种情况主要依赖CD8阳性的T细胞。更进一步的实验结果表明，在多克隆或抗原特异性CD8阳性T细胞中沉默PIM-2能够显着增强这些细胞在过继性T细胞免疫治疗中的抗肿瘤应答。

综上所述，PIM-2激酶在抑制T细胞应答方面发挥重要作用，这一发现为靶向PIM-2提高癌症免疫治疗效果提供了重要的理论支持。

原始出处：
Anusara Daenthanasanmak， et al. PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. JCI， https：//doi.org/10.1172/JCI95407.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1802549, encodeId=5de3180254917, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Oct 09 05:02:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051151, encodeId=61332051151d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 13 02:02:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288259, encodeId=99c6128825979, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582013, encodeId=b9b51582013a6, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318307, encodeId=aa3031830e93, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri May 25 06:24:31 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-10-09 旅苦化文_208

    #科学家发现#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1802549, encodeId=5de3180254917, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Oct 09 05:02:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051151, encodeId=61332051151d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 13 02:02:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288259, encodeId=99c6128825979, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582013, encodeId=b9b51582013a6, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318307, encodeId=aa3031830e93, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri May 25 06:24:31 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2019-02-13 xiangyuzhou971

    #EST#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1802549, encodeId=5de3180254917, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Oct 09 05:02:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051151, encodeId=61332051151d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 13 02:02:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288259, encodeId=99c6128825979, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582013, encodeId=b9b51582013a6, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318307, encodeId=aa3031830e93, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri May 25 06:24:31 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-26 lsndxfj

    #新靶点#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1802549, encodeId=5de3180254917, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Oct 09 05:02:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051151, encodeId=61332051151d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 13 02:02:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288259, encodeId=99c6128825979, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582013, encodeId=b9b51582013a6, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318307, encodeId=aa3031830e93, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri May 25 06:24:31 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-26 ms4468361851264128

    #华人#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1802549, encodeId=5de3180254917, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Oct 09 05:02:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051151, encodeId=61332051151d8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 13 02:02:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288259, encodeId=99c6128825979, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582013, encodeId=b9b51582013a6, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sat May 26 05:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318307, encodeId=aa3031830e93, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri May 25 06:24:31 CST 2018, time=2018-05-25, status=1, ipAttribution=)]
    2018-05-25 大爰

    学习了谢谢分享!!

    0

相关资讯

华人科学家鲍哲南获“世界杰出女科学家奖”

2017年度“世界杰出女科学家奖”颁奖典礼23日晚在巴黎举行，美国斯坦福大学华人教授鲍哲南和另外4位女科学家获得这一奖项。来自中国科技大学的博士后龙冉荣获“世界最具潜力女科学家奖”。联合国教科文组织总干事博科娃在发表视频致辞时表示：“每一位获奖者都激励我们加倍努力去推动女性对科学做出贡献，她们证明人类的进步不能仅仅依靠男性，我们应该行动起来，让女性能够在研究、行政、教学以及所有科学学科领域都自主独

华人科学家发现能永久阻止癌细胞增殖的基因

近日，凯斯西储大学医学院研究人员发现，当癌细胞中表达的基因Chk1发生突变后，在没有任何化疗药物干预下会导致癌细胞增殖永久性的停止，并引起细胞死亡。这项研究说明了一个前所未有的发现即人为地单独激活Chk1是足以杀死癌细胞的。 研究人员发现能永久阻止癌细胞增殖的基因 Chk1蛋白是细胞发育中的一个关卡(checkpoint)：阻止正常细胞和受损细胞发生分裂直到它们的DNA完全复制或修复。对于

牛！华人科学家同日连发6篇Cell！

今天是生命科学领域的又一个“中国日”！在今日出版的最新一期国际顶尖学术刊物《细胞》中，一共有10篇科研论文得到发表，其中5篇论文来自华人科学家的课题组，占到了半壁江山！此外，今天还有1篇来自华人科学家的研究在《细胞》上在线发表。更关键的是，这些科学家的绝大部分任职单位或通讯单位在中国。正如许多人所评论的那样，“中国生命科学正阔步前进！”1徐华强教授课题组Identification of Ph

Cell：对于这种“无药可治”的癌症突变，华人科学家或许找到了解决方案

在癌症研究领域，KRAS是最为知名的致癌基因之一：科学家们早就发现，在多种人类癌症里，这个基因都发生了突变。然而几十年来，经过数代研发人员的不懈努力，我们依然没有一款能够针对这个基因突变的有效分子。因此，KRAS突变也一度被业内认为是“无药可治”。